It therefore seems likely that the metabolic effects induced by elevated plasma apelin concentrations in metabolic diseases such as obesity and T2DM are, at least initially, part of a compensatory mechanism to maintain functions such as insulin sensitivity. Here, APLN is linked to type 2 diabetes mellitus.